Anemia, Hemolytic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Anemia, Hemolytic. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Anemia, Hemolytic receives a directional strategic score of 59/100, combining unmet need (63/100), competitive intensity (96/100, where higher means more competition) and market attractiveness (95/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).

The reproducible entity is Patsnap disease ID 5cf2d858b2bf42ec8b56948c67a304e1 with MeSH identifier D000743. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016–2023

1. DelveInsight. Warm autoimmune hemolytic anemia epidemiology forecast segmentation, treatment approaches, and WAIHA market forecast [Internet]. 2020 April 3 [cited Feb 15, 2024]. Available from: https://www.delveinsight.com/blog/ warm-autoimmune-ahemolytic-anemia-epidemiology-forecast 2. Hansen DL, Möller S, Andersen K, Gaist D, Frederiksen H. Increasing incidence and prevalence of acquired hemolytic anemias in Denmark, 1980- 2016. Clin Epidemiol. 2020;12:497–508. 3. Bylsma LC, Gulbech Ording A, Rosenthal A, Öztürk B, Fryzek JP, Arias JM, et al. Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. Blood Adv. 2019;3(20):2980–5. https://doi-org.sutd.idm.oclc.org/10.1182/bloodadvances.2019000476 PMID: 31648316 4. Hematology, ASH® Education Program. Autoimmune hemolytic anemia [Internet]. 2018 November 30 [cited Feb 15, 2024]. Available from: https:// ashpublications.org/hematology/article/2018/1/382/277583/Autoimmune-hemolytic-anemia 5. National Organization for Rare Disorders (NORD). [cited Feb 15, 2024]. Available from: https://rarediseases.org/. 6. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014;99(10):1547–54. https://doi-org.sutd.idm.oclc.org/10.3324/haema­ tol.2014.114561 PMID: 25271314 7. Barcellini W, Fattizzo B. The Changing Landscape of Autoimmune Hemolytic Anemia. Front Immunol. 2020;11:946. https://doi-org.sutd.idm.oclc.org/10.3389/ fimmu.2020.00946 PMID: 32655543 8. Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program. 2016;2016(1):226–31. https://doi-org.sutd.idm.oclc.org/10.1182/asheduca­ tion-2016.1.226 PMID: 27913484 9. Mic

Review the epidemiology source

Epidemiology evidence 2: Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980–2016 Increasing Incidence and Prevalence of AcquiredHemolytic Anemias in Denmark, 1980–2016

Results: Our analysis included 5868 patients with acquired hemolytic disorders (2715 with AIHA, 112 CAD, 397 DIHA, 116 PNH, and 2154 AHNOS). The incidence rates per 100 000 person-years in 1980–1993 and 2008–2016 were 0.81 and 1.77 for AIHA, 0.31 and 0.12 for DIHA, and 0.04 and 0.08 for PNH, respectively. The 2008–2016 CAD incidence rate was 0.18/100 000 person-years, CAD diagnosis code was not defined before 1994. All incidence rates increased with age. The prevalence proportion per 100 000 persons in 1980 and 2015 was 2.52 and 17.01 for AIHA, 0.80 and 1.50 for DIHA, and 0.18 and 1.04 for PNH. CAD prevalence in 2015 was 1.04/100 000 persons. Conclusion: Acquired hemolytic anemia incidence rates and prevalence proportions with the exception of DIHA are markedly increasing. Keywords: autoimmune hemolytic anemia, cold agglutinin disease, paroxysmal nocturnal hemoglobinuria, drug-induced hemolytic anemia, incidence, prevalence Introduction Acquired hemolytic disorders—comprising autoimmune hemolytic anemia (AIHA), cold agglutinin disease (CAD), paroxysmal nocturnal hemoglobinuria (PNH), drug- induced hemolysis, and acquired hemolysis not otherwise specified (NOS)—are considered rare and are reportedly associated with increased mortality.1–10 However, few data are available regarding the incidence and prevalence of these disorders. Two studies published in 1973 and 2010 describe an approximate AIHA incidence rate of 0.5–1 per 100 000 person-years1,2 but contemporary nationwide estimates are lacking. AIHA prevalence is also sparsely described.3 Similarly, CAD incidence is reported

Review the epidemiology source

Epidemiology evidence 3: Prevalence and factors associated with anemia among women of reproductive age in seven South and Southeast Asian countries: Evidence from nationally representative surveys Prevalence and factors associated withanemia among women of reproductive age inseven South and Southeast Asian countries:Evidence from nationally representativesurveys

The prevalence of anemia varies according to geographic regions. Sub-Saharan Africa (SSA) and South Asia had the highest prevalence of anemia across all age groups [9]. Likewise, at the country level, anemia among WRA is a moderate-to-severe public health problem (20% or greater as defined by WHO) in the majority of the developing countries [2,10]. Determi- nants and distribution of prevalence of anemia in a population include a complex interplay of political, ecological, social, and biological factors [4]. In most of the countries, anemia varies by socioeconomic factors such as education, household wealth status, occupation, and resi- dence [2,6]. A pooled analysis conducted by Balarajan et al [6] reported that the risk of anemia among women living in the lowest wealth quintile, with no education, and also differed by urban or rural settings. Likewise, previous studies have highlighted the probable causes of ane- mia among women including undernutrition, repeated childbearing, pregnant and lactation, inadequate dietary intake during pregnancy, inadequate water hygiene and sanitation status, rural residency, and parasitic infection [11–13]. Though several causes are associated with ane- mia, iron deficiency anemia is the most common type of anemia worldwide that is usually caused by inadequate intake of iron-rich foods in regular diets and excessive loss of red blood cells or a combination of both [3]. Various studies conducted from the developing countries have reported a high prevalence of iron deficiency anemia among pregnant women [14,15]. In low and middle-income count

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Anemia, Hemolytic, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Anemia, Hemolytic thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: C5

Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:6554279). Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:39914456, PubMed:39814882, PubMed:6554279). Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed:26841837, PubMed:27052168, PubMed:30552328, PubMed:30643019). Complement C5b is generated following cleavage by C5 convertase and initiates formation of the MAC complex: C5b binds sequentially C6, C7, C8 and multiple copies of the pore-forming subunit C9 (PubMed:30552328, PubMed:30643019). During MAC complex assembly, the C5b6 subcomplex, composed of complement C5b and C6, associates with the outer leaflet of target cell membrane, reducing the energy for membrane bending (PubMed:30552328, PubMed:32569291). Mediator of local inflammatory process released following cleavage by C5 convertase (PubMed:8182049, PubMed:9553099). Acts by binding to its receptor (C5AR1 or C5AR2), activating G protein-coupled receptor signaling and inducing a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:36806352, PubMed:37852260, PubMed:37169960, PubMed:8182049, PubMed:9553099). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation (PubMed:342601, PubMed:37852260, PubMed:37169960, PubMed:5765461, PubMed:8182049, PubMed:9553099).

The mechanism anchor is C5. It is a pathway hypothesis, not a claim that every Anemia, Hemolytic patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 2866 registered studies. Recent sampled records include:

• NCT07776444 — Cerebrovascular Reactivity Measurements With High-Density Diffuse Optical Tomography (HDDOT CVR); Recruiting; Not Applicable; sponsor Washington University School of Medicine; enrollment 120.
• NCT07774351 — A Clinical Exploratory Study of YOLT-204 in the Treatment of Hemoglobinopathies; Not yet recruiting; Not Applicable; sponsor Wuhan Union Hospital; enrollment 30.
• CTR20263129 — 评估皮下给药SGB-9768注射液的安全性、耐受性、药代动力学和药效学II期临床研究; 进行中 （尚未招募）; Phase 2; sponsor Sanegene Bio (Suzhou) Co., Ltd.; enrollment Target enrollment: 国内: 30  Enrolled: 国内: 登记人暂未填写该信息 Actual enrollment: 国内: 登记人暂未填写该信息.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

The search returned 7 recent directly matched transaction records:

• Xcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell disease (2025-04-02). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.
• IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases (2025-01-22). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.
• Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) (2025-01-07). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate C5 relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Anemia, Hemolytic merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if C5 modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Anemia, Hemolytic is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.